BIOCON
₹240.65
  • Advice
  • Hold
As on 05 December, 2023 | 07:24 BSE: 532523 NSE: BIOCONISIN: INE376G01013

Biocon Performance

Day Range

  • Low 238.90
  • High 243.40
₹ 240.65

52 Week Range

  • Low 191.55
  • High 285.30
₹ 240.65
  • Open Price243.30
  • Previous Close240.65
  • Volume1817846

Start SIP in Biocon

Start SIP

Biocon Share Price

  • Over 1 Month 7.19%
  • Over 3 Month -7.92%
  • Over 6 Month 0.17%
  • Over 1 Year -15.13%

Biocon Key Statistics

P/E Ratio 58
PEG Ratio -3
Market Cap Cr 28,892
Price to Book Ratio 1.3
EPS -0.1
Dividend 0.6
Relative Strength Index 58.75
Money Flow Index 64.21
MACD Signal -1.48
Average True Range 5.01

Biocon Investment Rating

  • Master Rating:
  • Biocon (Nse) has an operating revenue of Rs. 13,599.90 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 10% is healthy, ROE of 2% is fair but needs improvement. The company has a debt to equity of 86%, which is bit higher. The stock from a technical standpoint is trading close to its key moving averages, around -0% and -0% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 60 which is a FAIR score but needs to improve its earnings, a RS Rating of 16 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 112 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Biocon Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 519513507555490442518
Operating Expenses Qtr Cr 452441551518462439491
Operating Profit Qtr Cr 6772-443728327
Depreciation Qtr Cr 31302929302928
Interest Qtr Cr 55484821000
Tax Qtr Cr 113-1511119821
Net Profit Qtr Cr 35471,811359881538
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 2,2641,925
Operating Expenses Annual Cr 1,9691,677
Operating Profit Annual in Cr 2461
Depreciation Cr 117108
Interest Annual Cr 700
Tax Annual Cr 12354
Net Profit Annual Cr 2,84886
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 21948
Cash from Investing Activity Annual Cr -1,178-306
Cash from Financing Annual Activity Cr 1,039112
Net Cash Flow Annual Cr 81-146
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 10,9168,093
Fixed Assets Annual Cr 1,3051,155
Total Non Current Assets Annual Cr 10,4646,467
Total Current Assets Annual Cr 2,5662,402
Total Assets Annual Cr 13,0308,869
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 9167
ROE Annual % 261
ROCE Annual % 12
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1514
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 3,4623,4233,7742,9412,3202,1402,409
Operating Expenses Qtr Cr 2,7212,7082,7772,2971,8491,7401,817
Operating Profit Qtr Cr 742714997644471399592
Depreciation Qtr Cr 389358364301231218212
Interest Qtr Cr 248233249120302011
Tax Qtr Cr 423582-51473059
Net Profit Qtr Cr 126101313-4247144239
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 11,5508,397
Operating Expenses Annual Cr 8,6636,214
Operating Profit Annual in Cr 2,5121,970
Depreciation Cr 1,113814
Interest Annual Cr 41968
Tax Annual Cr 254212
Net Profit Annual Cr 463648
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 1,8531,177
Cash from Investing Activity Annual Cr -14,282-1,699
Cash from Financing Annual Activity Cr 13,049242
Net Cash Flow Annual Cr 619-280
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 17,8678,433
Fixed Assets Annual Cr 20,64910,653
Total Non Current Assets Annual Cr 39,70912,012
Total Current Assets Annual Cr 12,3348,382
Total Assets Annual Cr 52,04320,394
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 18779
ROE Annual % 38
ROCE Annual % 48
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2627

Biocon Technicals

EMA & SMA

Current Price
₹240.65
0 (0%)
pointer
  • Bullish Moving Average
  • ___
  • 10
  • Bearish Moving Average
  • ___
  • 6
  • 20 Day
  • ₹235.03
  • 50 Day
  • ₹239.89
  • 100 Day
  • ₹244.88
  • 200 Day
  • ₹251.29
  • 20 Day
  • ₹232.58
  • 50 Day
  • ₹241.69
  • 100 Day
  • ₹251.64
  • 200 Day
  • ₹242.41

Biocon Resistance and Support

PIVOT
₹240.99
Resistance
First Resistance 243.07
Second Resistance 245.48
Third Resistance 247.57
RSI 58.75
MFI 64.21
MACD Single Line -1.48
MACD 0.42
Support
First Resistance 238.57
Second Resistance 236.48
Third Resistance 234.07

Biocon Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,924,667 83,126,368 43.19
Week 2,916,723 145,019,458 49.72
1 Month 3,181,947 134,723,640 42.34
6 Month 3,705,818 167,317,675 45.15

Biocon Result Highlights

Biocon Synopsis

NSE-Medical-Biomed/Biotech

Biocon is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1992.90 Cr. and Equity Capital is Rs. 600.30 Cr. for the Year ended 31/03/2023. Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24234KA1978PLC003417 and registration number is 003417.
Market Cap 28,892
Sales 2,094
Shares in Float 46.82
No of funds 268
Yield 0.62
Book Value 2.65
U/D Vol ratio 0.8
LTDebt / Equity 12
Alpha -0.09
Beta 0.89

Biocon

Owner NameSep-23Jun-23Mar-23Dec-22
Promoters 60.64%60.64%60.64%60.64%
Mutual Funds 8.26%7.47%7.19%3.95%
Insurance Companies 5.76%5.09%4.68%4.68%
Foreign Portfolio Investors 7.97%9.52%10.2%14.42%
Financial Institutions/ Banks
Individual Investors 13.61%13.34%13.2%12.47%
Others 3.76%3.94%4.09%3.84%

Biocon Management

Name Designation
Ms. Kiran Mazumdar Shaw Executive Chairperson
Mr. Siddharth Mittal Managing Director & CEO
Prof. Ravi Rasendra Mazumdar Non Exe.Non Ind.Director
Mr. Eric Vivek Mazumdar Non Exe.Non Ind.Director
Mr. Meleveetil Damodaran Lead Independent Director
Dr. Vijay Kumar Kuchroo Independent Director
Mr. Bobby Kanubhai Parikh Independent Director
Mr. Peter John Bains Independent Director
Mr. Naina Lal Kidwai Independent Director

Biocon Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Biocon Corporate Action

Date Purpose Remarks
2023-11-10 Quarterly Results
2023-08-10 Quarterly Results
2023-05-23 Audited Results & Final Dividend
2023-04-26 Others To consider, Fund Raising. per share(20%)Final Dividend (Rs.0.5000 per share(10%)Final Dividend (Post Bonus Issue))
2023-02-14 Quarterly Results
Date Purpose Remarks
2023-07-07 FINAL Rs.1.50 per share(30%)Final Dividend
2022-07-01 FINAL Rs.0.50 per share(10%)Final Dividend

Biocon MF Shareholding

Name Amount(cr)
Mirae Asset Large Cap Fund Regular Growth 34,377
Kotak Equity Arbitrage Fund Growth 28,958
ICICI Prudential Multi-Asset Fund Growth 24,931
SBI Balanced Advantage Fund Regular Growth 24,344
SBI Arbitrage Opportunities Fund Regular Growth 22,370

About Biocon

Biocon limited is a biopharmaceutical company in India and it is Asia's largest biotechnology company. The company was founded by Kiran Mazumdar-Shaw in 1978 and is headquartered in Bangalore, India. The company has more than 13,500  employees. It focuses on all phases of the product cycle from researching to development and then introducing them to the market.  They mainly concentrate on the research and development of advanced therapies for the treatment of cancer, diabetes, and autoimmune disease. The company's medicines are helping the lives of patients in more than 120 countries by providing access to all their medicines and therapies. 

Some of Biocon's important brands in India are INSUGEN (rh-insulin), BIOMAb EGFR (Nimotuzumab), CANMAb (Trastuzumab),KRABEVA (Bevacizumab), ALZUMAb(Itolizumab), BLISTO (Glimepiride + Metformin), BASALOG (Glargine), etc. 

Biocon FAQs

What is Share Price of Biocon ?

Biocon share price is ₹240 As on 05 December, 2023 | 07:10

What is the Market Cap of Biocon ?

The Market Cap of Biocon is ₹28892.4 Cr As on 05 December, 2023 | 07:10

What is the P/E ratio of Biocon ?

The P/E ratio of Biocon is 58 As on 05 December, 2023 | 07:10

What is the PB ratio of Biocon ?

The PB ratio of Biocon is 1.3 As on 05 December, 2023 | 07:10

Is it a good time to invest in Biocon Limited?

Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.

How many times has Biocon Limited given dividends since 2004?

Biocon Ltd. has declared 17 dividends since July 1, 2004.

What is the stock price CAGR of Biocon Limited?

The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.

What is the debt-to-equity ratio of Biocon Limited?

The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.

What is the ROE of the Biocon Limited?

The ROE of Biocon Limited is 9% which is fair but needs improvement.

Who is the Managing Director of Biocon Limited?

Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.

Is Biocon a good stock to buy?

According to the record analysis of moneyworks4me, Biocom limited is an average quality company. 

How to buy shares of Biocon Ltd?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

Q2FY23